BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vignon P, Laterre PF, Daix T, François B. New Agents in Development for Sepsis: Any Reason for Hope? Drugs 2020;80:1751-61. [PMID: 32951149 DOI: 10.1007/s40265-020-01402-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Bradley Z, Bhalla N. Point-of-care diagnostics for sepsis using clinical biomarkers and microfluidic technology. Biosens Bioelectron 2023;227:115181. [PMID: 36867959 DOI: 10.1016/j.bios.2023.115181] [Reference Citation Analysis]
2 Kharga K, Kumar L, Patel SKS. Recent Advances in Monoclonal Antibody-Based Approaches in the Management of Bacterial Sepsis. Biomedicines 2023;11:765. [DOI: 10.3390/biomedicines11030765] [Reference Citation Analysis]
3 Berlot G, Tomasini A, Zanchi S, Moro E. The Techniques of Blood Purification in the Treatment of Sepsis and Other Hyperinflammatory Conditions. J Clin Med 2023;12. [PMID: 36902510 DOI: 10.3390/jcm12051723] [Reference Citation Analysis]
4 Firzli TR, Sathappan S, Antwi-amoabeng D, Beutler BD, Ulanja MB, Madhani-lovely F. Association between histamine 2 receptor antagonists and sepsis outcomes in ICU patients: a retrospective analysis using the MIMI-IV database. J Anesth Analg Crit Care 2023;3:3. [DOI: 10.1186/s44158-023-00089-4] [Reference Citation Analysis]
5 Joshi I, Carney WP, Rock EP. Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis. Front Immunol 2023;14:1130214. [PMID: 36825018 DOI: 10.3389/fimmu.2023.1130214] [Reference Citation Analysis]
6 Yu T, Tang Y, Zhang F, Zhang L. Roles of ginsenosides in sepsis. J Ginseng Res 2023;47:1-8. [PMID: 36644389 DOI: 10.1016/j.jgr.2022.05.004] [Reference Citation Analysis]
7 Hai PD, Viet Hoa LT, Luchette FA. The Prognostic Accuracy Evaluation of mNUTRIC, APACHE II, SOFA, and SAPS 2 Scores for Mortality Prediction in Patients with Sepsis. Critical Care Research and Practice 2022;2022:1-7. [DOI: 10.1155/2022/4666594] [Reference Citation Analysis]
8 Rumienczyk I, Kulecka M, Statkiewicz M, Ostrowski J, Mikula M. Oncology Drug Repurposing for Sepsis Treatment. Biomedicines 2022;10:921. [DOI: 10.3390/biomedicines10040921] [Reference Citation Analysis]
9 Rajpoot S, Srivastava G, Siddiqi MI, Saqib U, Parihar SP, Hirani N, Baig MS. Identification of novel inhibitors targeting TIRAP interactions with BTK and PKCδ in inflammation through an in silico approach. SAR QSAR Environ Res 2022;:1-26. [PMID: 35174746 DOI: 10.1080/1062936X.2022.2035817] [Reference Citation Analysis]
10 Bruno MEC, Mukherjee S, Stromberg AJ, Saito H, Starr ME. Visceral fat-specific regulation of plasminogen activator inhibitor-1 in aged septic mice. J Cell Physiol 2022;237:706-19. [PMID: 34369600 DOI: 10.1002/jcp.30551] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Koch SR, Stark RJ. Cell penetrating peptides coupled to an endothelial nitric oxide synthase sequence alter endothelial permeability. Tissue Barriers 2021;:2017226. [PMID: 34923902 DOI: 10.1080/21688370.2021.2017226] [Reference Citation Analysis]
12 Lee AOCJ, Chua AHY, Sultana R, Lee JH, Wong JJM. Immunomodulator use in paediatric severe sepsis and septic shock. Ann Acad Med Singap 2021;50:765-772. [DOI: 10.47102/annals-acadmedsg.2021178] [Reference Citation Analysis]
13 Koufakis T, Maltese G, Metallidis S, Zebekakis P, Kotsa K. Looking deeper into the findings of DARE-19: Failure or an open door to future success? Pharmacol Res 2021;173:105872. [PMID: 34487851 DOI: 10.1016/j.phrs.2021.105872] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
14 Gulati A, Choudhuri R, Gupta A, Singh S, Ali SKN, Sidhu GK, Haque PD, Rahate P, Bothra AR, Singh GP, Maheshwari S, Jeswani D, Haveri S, Agarwal A, Agrawal NR. A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients. Drugs 2021;81:1079-100. [PMID: 34061314 DOI: 10.1007/s40265-021-01547-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Gulati A, Choudhuri R, Gupta A, Singh S, Noushad Ali SK, Sidhu GK, Haque PD, Rahate P, Bothra AR, Singh GP, Maheshwari S, Jeswani D, Haveri S, Agarwal A, Agrawal NR. A multicentric, randomized, controlled phase III study of centhaquine (Lyfaquin ® ) as a resuscitative agent in hypovolemic shock patients. medRxiv 2021:2020. [PMID: 33173916 DOI: 10.1101/2020.07.30.20068114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Leong K, Gaglani B, Khanna AK, McCurdy MT. Novel Diagnostics and Therapeutics in Sepsis. Biomedicines 2021;9:311. [PMID: 33803628 DOI: 10.3390/biomedicines9030311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]